In this experiment, they observed different expression of transcripts between the vandetanib-sensitive and vandetanib-resistant cell lines, including multidrug-resistance 1 (which confers drug resistance in other cancers) and autotaxin (promotes cell survival), and an enrichment of the proteasome pathway (as a potential candidate of growth suppression by vandetanib), which was validated via exposure of the cell lines to bortezomib, thus suggesting that PrIns can be a potential therapeutic strategy for overcoming resistance. The gene discussed is ENPP2; the disease is cancer.